MedPath

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

Phase 2
Recruiting
Conditions
TNBC - Triple-Negative Breast Cancer
Interventions
Drug: Fluzoparib+Paclitaxel
Drug: Epirubicin+Cyclophosphamide
Registration Number
NCT05834582
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Brief Summary

Although many PARP inhibitors did not improve pCR in neoadjuvant studies, it is not an unchallenged conclusion that TNBC does not benefit from use of PARP inhibitors in neoadjuvant therapy.This study is an open-label, two-cohort, multicenter trial. 60 patients with germline BRCA-mutated three-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with chemotherapy according to tumor response after EC (epirubicin and cyclophosphamide) for 2 cycles.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
60
Inclusion Criteria
  1. Women ≥ 18 and ≤ 70 years of age with treatment-naïve breast cancer

  2. Histopathologically confirmed early or locally advanced three-negative invasive breast cancer as defined by the ASCO/CAP guidelines while meeting the following conditions:

    HER2 negative: IHC 0/1 + or IHC2 + but ISH negative; ER and/or PR negative (not eligible for endocrine therapy): IHC nuclear staining ≤ 1%

  3. Tumor stage: II-III: Primary tumor size: ≥ 2cm

  4. ECOG score 0 ~ 1;

  5. Centrally confirmed BRCA1 or BRCA2 germline mutation;

  6. Eligible level of organ function

Exclusion Criteria
  1. Patients with metastatic breast cancer or bilateral breast cancer or inflammatory breast cancer;
  2. Participated in other drug trials or received any anti-tumor therapy within 4 weeks before enrollment, including endocrine therapy, immunotherapy, biological therapy or tumor embolization;
  3. Previously received PARPi therapy;
  4. History of another primary malignancy;
  5. Confirmed history of heart failure or systolic dysfunction (LVEF < 50%); high risk uncontrolled cardiac arrhythmias, such as atrial tachycardia;
  6. Female patients who are pregnant or lactating;
  7. History of allergy to drugs in this study;

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Cohort1: Epirubicin+CyclophosphamideEpirubicin+Cyclophosphamide2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is CR or PR: Epirubicin+Cyclophosphamide for 2 cycles Fluzoparib+Paclitaxel for 2 cycles
Cohort2: Fluzoparib+PaclitaxelFluzoparib+Paclitaxel2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is SD: Fluzoparib+Paclitaxel for 4 cycles
Cohort2: Fluzoparib+PaclitaxelEpirubicin+Cyclophosphamide2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is SD: Fluzoparib+Paclitaxel for 4 cycles
Cohort1: Epirubicin+CyclophosphamideFluzoparib+Paclitaxel2 cycles of EC (Epirubicin+Cyclophosphamide) induced chemotherapy, if tumor response is CR or PR: Epirubicin+Cyclophosphamide for 2 cycles Fluzoparib+Paclitaxel for 2 cycles
Primary Outcome Measures
NameTimeMethod
tpCR(ypT0/is ypN0)6 months from the patients enrolled

pCR is defined as the absence of invasive residual disease in the breast and in the axillary lymph nodes (ypT0/is ypN0).

Secondary Outcome Measures
NameTimeMethod
Event-free Survival (EFS) as assessed by InvestigatorUp to approximately 3 years

EFS is defined as the time from enrollment to disease progression or death due to any cause

AEs and SAEsFrom enrollment to the surgery (approximately 6 months)

adverse events and serious adverse events

Trial Locations

Locations (1)

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath